8th Aug 2018 12:05
LONDON (Alliance News) - Genedrive PLC said Wednesday it partnered with the Foundation for Innovation of New Diagnostics, or FIND, which will evaluate its hepatitis C virus kit.
The company's kit is a qualitative hepatitis C virus diagnostic assay, performed on its portable molecular diagnostics platform, Genedrive explained.
It delivers results in 90 minutes and it is designed to be used in low-resource settings.
Under the agreement, FIND will lead evaluation studies of the kit in Cameroon and Georgia starting from September.
"These studies are designed to confirm the diagnostic accuracy of Genedrive HCV ID across diverse genotypes, as well as to assess usability in the intended market setting," Gendrive said.
Genedrive shares were trading 4.3% higher at 31.80 pence each.
Related Shares:
Genedrive